Exploring NMR ensembles of calcium binding proteins: Perspectives to design inhibitors of protein-protein interactions

BMC Structural Biology

Volumn 11, Issue , 2011, Pages

  Isvoran, Adriana ^a,b   Badel, Anne ^a,c,d   Miron, Simona ^c,d   Miteva, Maria A ^a   Craescu, Constantin T ^a  

^a INSERM   (France)

^b WEST UNIVERSITY OF TIMISOARA   (Romania)

^c INSTITUT CURIE   (France)

^d Centre Universitaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN; CENTRIN; CENTRIN 2; LIGAND; TERPHENYL DERIVATIVE; UNCLASSIFIED DRUG; CALCIUM; COTRIMOXAZOLE;

ALPHA HELIX; CELL FUNCTION; COMPUTER MODEL; CONFORMATIONAL TRANSITION; LIGAND BINDING; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; HUMAN; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN DOMAIN; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; THERMODYNAMICS;

AMINO ACID SEQUENCE; BINDING SITES; CALCIUM; CALMODULIN; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; PROTEIN INTERACTION DOMAINS AND MOTIFS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; THERMODYNAMICS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 79955798852     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-11-24     Document Type: Review

References (67)

1. Estimating the size of the human interactome. MP Stumpf T Thorne E de Silva R Stewart HJ An M Lappe C Wiuf, Proc Natl Acad Sci USA 2008 105 6959 6964 10.1073/pnas.0708078105 18474861 (Pubitemid 351754512)
2. Protein-protein interfaces: mimics and inhibitors. AG Cochran, Curr Opin Chem Biol 2001 5 654 659 10.1016/S1367-5931(01)00262-9 11738175 (Pubitemid 33153162)
3. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. JA Wells CL McClendon, Nature 2007 450 1001 1009 10.1038/nature06526 18075579 (Pubitemid 350273630)
4. In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. BO Villoutreix K Bastard O Sperandio R Fahraeus JL Poyet F Calvo B Deprez MA Miteva, Curr Pharm Biotechnol 2008 9 103 122 10.2174/138920108783955218 18393867 (Pubitemid 351513489)
5. Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. R Bourgeas MJ Basse X Morelli P Roche, PLoS One 2010 5 9598 10.1371/journal.pone.0009598 20231898
6. Predicting druggable binding sites at the protein-protein interface. JC Fuller NJ Burgoyne RM Jackson, Drug Discov Today 2009 14 155 161 10.1016/j.drudis.2008.10.009 19041415
7. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. C Reynes H Host AC Camproux G Laconde F Leroux A Mazars B Deprez R Fahraeus BO Villoutreix O Sperandio, PLoS Comput Biol 2010 6 1000695 10.1371/journal.pcbi.1000695 20221258
8. Rationalizing the chemical space of protein-protein interaction inhibitors. O Sperandio CH Reynes AC Camproux BO Villoutreix, Drug Discov Today 2010 15 220 229 10.1016/j.drudis.2009.11.007 19969101
9. Simultaneous binding of drugs with different chemical structures to Ca2+-calmodulin: crystallographic and spectroscopic studies. BG Vertessy V Harmat Z Bocskei G Naray-Szabo F Orosz J Ovadi, Biochemistry 1998 37 15300 15310 10.1021/bi980795a 9799490 (Pubitemid 28515990)
10. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. O Kutzki HS Park JT Ernst BP Orner H Yin AD Hamilton, J Am Chem Soc 2002 124 11838 11839 10.1021/ja026861k 12358513
11. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. H Yin GI Lee KA Sedey O Kutzki HS Park BP Orner JT Ernst HG Wang SM Sebti AD Hamilton, J Am Chem Soc 2005 127 10191 10196 10.1021/ja050122x 16028929 (Pubitemid 41045484)
12. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. BP Orner JT Ernst AD Hamilton, J Am Chem Soc 2001 123 5382 5383 10.1021/ja0025548 11457415 (Pubitemid 32910693)
13. Calmodulin Target Database. KL Yap J Kim K Truong M Sherman T Yuan M Ikura, J Stru Funct Gen 2000 1 8 14 10.1023/A:1011320027914
14. Calmodulin: a prototypical calcium sensor. D Chin AR Means, Trends Cell Biol 2000 10 322 328 10.1016/S0962-8924(00)01800-6 10884684 (Pubitemid 30445239)
15. Conformation and free energy analyses of the complex of calcium-bound calmodulin and the Fas death domain. JD Suever Y Chen JM McDonald Y Song, Biophys J 2008 95 5913 5921 10.1529/biophysj.108.130542 18820240
16. Target enzyme recognition by calmodulin: 2.4 A structure of a calmodulin-peptide complex. WE Meador AR Means FA Quiocho, Science 1992 257 1251 1255 10.1126/science.1519061 1519061
17. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. CL Drum SZ Yan J Bard YQ Shen D Lu S Soelaiman Z Grabarek A Bohm WJ Tang, Nature 2002 415 396 402 10.1038/415396a 11807546 (Pubitemid 34100945)
18. C-terminal half of human centrin 2 behaves like a regulatory EF-hand domain. E Matei S Miron Y Blouquit P Duchambon I Durussel JA Cox CT Craescu, Biochemistry 2003 42 1439 1450 10.1021/bi0269714 12578356 (Pubitemid 36205950)
19. Target selectivity in EF-hand calcium binding proteins. S Bhattacharya CG Bunick WJ Chazin, Biochim Biophys Acta 2004 1742 69 79 10.1016/j.bbamcr.2004. 09.002 15590057 (Pubitemid 39601767)
20. Calmodulin inhibitors from the fungus Emericella sp. M Figueroa C Gonzalez Mdel R Rodriguez-Sotres A Sosa-Peinado M Gonzalez-Andrade CM Cerda-Garcia-Rojas R Mata, Bioorg Med Chem 2009 17 2167 2174 10.1016/j.bmc.2008.10.079 19013822
21. Centrin-2 is required for centriole duplication in mammalian cells. JL Salisbury KM Suino R Busby M S, Curr Biol 2002 12 1287 1292 10.1016/S0960- 9822(02)01019-9 12176356 (Pubitemid 34869878)
22. Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates global genome nucleotide excision repair. M Araki C Masutani M Takemura A Uchida K Sugasawa J Kondoh Y Ohkuma F Hanaoka, J Biol Chem 2001 276 18665 18672 10.1074/jbc.M100855200 11279143
23. Centrin 2 localizes to the vertebrate nuclear pore and plays a role in mRNA and protein export. KK Resendes BA Rasala DJ Forbes, Moll Cel Biol 2008 28 1755 1769 10.1128/MCB.01697-07
24. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. JS Saldivar X Wu M Follen D Gershenson, Gynecol Oncol 2007 107 56 71 10.1016/j.ygyno.2007.07.043 17884153
25. Centrin 2 Stimulates Nucleotide Excision Repair by Interacting with Xeroderma Pigmentosum Group C Protein. R Nishi Y Okuda E Watanabe T Mori S Iwai C Masutani K Sugasawa F Hanaoka, Moll Cel Biol 2005 25 5664 5674 10.1128/MCB.25.13.5664-5674.2005 (Pubitemid 40853600)
26. Structural, thermodynamic, and cellular characterization of human centrin 2 interaction with xeroderma pigmentosum group C protein. JB Charbonnier E Renaud S Miron MH Le Du Y Blouquit P Duchambon P Christova A Shosheva T Rose JF Angulo CT Craescu, J Mol Biol 2007 373 1032 1046 10.1016/j.jmb.2007.08.046 17897675 (Pubitemid 47500171)
27. Virtual screening of chemical libraries. BK Shoichet, Nature 2004 432 862 865 10.1038/nature03197 15602552 (Pubitemid 40037142)
28. Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections. M Montes MA Miteva BO Villoutreix, Proteins 2007 68 712 725 10.1002/prot.21405 17510958 (Pubitemid 47068310)
29. Structure-based virtual ligand screening: recent success stories. BO Villoutreix R Eudes MA Miteva, Combinatorial Chemistry & High Throughput Screening 2009 12 1000 1016 10.2174/138620709789824682 21567500
30. Flexible ligand docking to multiple receptor conformations: a practical alternative. M Totrov R Abagyan, Curr Opin Struct Biol 2008 18 178 184 10.1016/j.sbi.2008.01.004 18302984
31. Principal component analysis of native ensembles of biomolecular structures (PCA-NEST): insights into functional dynamics. LW Yang E Eyal I Bahar A Kitao, Bioinformatics 2009 25 606 614 10.1093/bioinformatics/btp023 19147661
32. Unveiling the full potential of flexible receptor docking using multiple crystallographic structures. X Barril SD Morley, J Med Chem 2005 48 4432 4443 10.1021/jm048972v 15974595 (Pubitemid 40884945)
33. Exploring experimental sources of multiple protein conformations in structure-based drug design. KL Damm HA Carlson, J Am Chem Soc 2007 129 8225 8235 10.1021/ja0709728 17555316 (Pubitemid 47039084)
34. Recipes for the selection of experimental protein conformations for virtual screening. M Rueda G Bottegoni R Abagyan, J Chem Inf Model 2010 50 186 193 10.1021/ci9003943 20000587
35. Docking of flexible ligands to flexible receptors in solution by molecular dynamics simulation. M Mangoni D Roccatano A Di Nola, Proteins 1999 35 153 162 10.1002/(SICI)1097-0134(19990501)35:2<153::AID-PROT2 3.0.CO;2-E 10223288 (Pubitemid 29165129)
36. The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme. JH Lin AL Perryman JR Schames JA McCammon, Biopolymers 2003 68 47 62 10.1002/bip.10218 12579579 (Pubitemid 36098307)
37. Representing receptor flexibility in ligand docking through relevant normal modes. CN Cavasotto JA Kovacs RA Abagyan, J Am Chem Soc 2005 127 9632 9640 10.1021/ja042260c 15984891 (Pubitemid 40934775)
38. Insights into protein flexibility: The relationship between normal modes and conformational change upon protein-protein docking. SE Dobbins VI Lesk MJ Sternberg, Proc Natl Acad Sci USA 2008 105 10390 10395 10.1073/pnas.0802496105 18641126
39. How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. O Sperandio L Mouawad E Pinto BO Villoutreix D Perahia MA Miteva, Eur Biophys J 2010 39 1365 1372 10.1007/s00249-010-0592-0 20237920
40. Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. G Bottegoni I Kufareva M Totrov R Abagyan, J Med Chem 2009 52 397 406 10.1021/jm8009958 19090659
41. In pursuit of virtual lead optimization: the role of the receptor structure and ensembles in accurate docking. ES Bolstad AC Anderson, Proteins 2008 73 566 580 10.1002/prot.22081 18473360 (Pubitemid 352788641)
42. Cation- and peptide-binding properties of human centrin 2. I Durussel Y Blouquit S Middendorp CT Craescu JA Cox, FEBS Lett 2000 472 208 212 10.1016/S0014-5793(00)01452-6 10788612 (Pubitemid 30224465)
43. NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. B Elshorst M Hennig H Forsterling A Diener M Maurer P Schulte H Schwalbe C Griesinger J Krebs H Schmid T Vorherr E Carafoli, Biochemistry 1999 38 12320 12332 10.1021/bi9908235 10493800
44. The structure of the human centrin 2-xeroderma pigmentosum group C protein complex. JR Thompson ZC Ryan JL Salisbury R Kumar, J Biol Chem 2006 281 18746 18752 10.1074/jbc.M513667200 16627479 (Pubitemid 44035535)
45. Development and validation of a modular, extensible docking program: DOCK 5. DT Moustakas PT Lang S Pegg E Pettersen ID Kuntz N Brooijmans RC Rizzo, J Comput Aided Mol Des 2006 20 601 619 10.1007/s10822-006-9060-4 17149653 (Pubitemid 46023925)
46. Structure, dynamics and thermodynamics of the human centrin 2/hSfi1 complex. J Martinez-Sanz F Kateb L Assairi Y Blouquit G Bodenhausen D Abergel L Mouawad CT Craescu, J Mol Biol 2010 395 191 204 10.1016/j.jmb.2009.10.041 19857500
47. Substitution of the methionine residues of calmodulin with the unnatural amino acid analogs ethionine and norleucine: biochemical and spectroscopic studies. T Yuan HJ Vogel, Protein Sci 1999 8 113 121 10210190 (Pubitemid 29035525)
48. Flexibility and plasticity of human centrin 2 binding to the xeroderma pigmentosum group C protein (XPC) from nuclear excision repair. A Yang S Miron L Mouawad P Duchambon Y Blouquit CT Craescu, Biochemistry 2006 45 3653 3663 10.1021/bi0524868 16533048
49. Fpocket: an open source platform for ligand pocket detection. V Le Guilloux P Schmidtke P Tuffery, BMC Bioinformatics 2009 10 168 10.1186/1471-2105-10-168 19486540
50. Physics-based scoring of protein-ligand complexes: enrichment of known inhibitors in large-scale virtual screening. N Huang C Kalyanaraman JJ Irwin MP Jacobson, J Chem Inf Model 2006 46 243 253 10.1021/ci0502855 16426060 (Pubitemid 43282119)
51. Post-docking virtual screening of diverse binding pockets: comparative study using DOCK, AMMOS, X-Score and FRED scoring functions. T Pencheva OS Soumana I Pajeva MA Miteva, Eur J Med Chem 2010 45 2622 2628 10.1016/j.ejmech.2009.12.025 20227800
52. AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening. T Pencheva D Lagorce I Pajeva BO Villoutreix MA Miteva, BMC Bioinformatics 2008 9 438 10.1186/1471-2105-9-438 18925937
53. Protein flexibility in ligand docking and virtual screening to protein kinases. CN Cavasotto RA Abagyan, J Mol Biol 2004 337 209 225 10.1016/j.jmb.2004.01.003 15001363 (Pubitemid 38270258)
54. X-Score. http://www.sioc-ccbg.ac.cn/software/xscore/
55. Investigation of MM-PBSA rescoring of docking poses. DC Thompson C Humblet D Joseph-McCarthy, J Chem Inf Model 2008 48 1081 1091 10.1021/ci700470c 18465849
56. The Protein Data Bank. HM Berman J Westbrook Z Feng G Gilliland TN Bhat H Weissig IN Shindyalov PE Bourne, Nucleic Acids Res 2000 28 235 242 10.1093/nar/28.1.235 10592235 (Pubitemid 30047768)
57. Calmodulin structure refined at 1.7 A resolution. R Chattopadhyaya WE Meador AR Means FA Quiocho, J Mol Biol 1992 228 1177 1192 10.1016/0022-2836(92) 90324-D 1474585 (Pubitemid 23018499)
58. A coupled equilibrium shift mechanism in calmodulin-mediated signal transduction. J Gsponer J Christodoulou A Cavalli JM Bui B Richter CM Dobson M Vendruscolo, Structure 2008 16 736 746 10.1016/j.str.2008.02.017 18462678 (Pubitemid 351615020)
59. PCE: web tools to compute protein continuum electrostatics. MA Miteva P Tuffery BO Villoutreix, Nucleic Acids Res 2005 33 372 375 10.1093/nar/gki365 15980492
60. UCSF Chimera - a visualization system for exploratory research and analysis. EF Pettersen TD Goddard CC Huang GS Couch DM Greenblatt EC Meng TE Ferrin, J Comput Chem 2004 25 1605 1612 10.1002/jcc.20084 15264254
61. DMS. http://www.cgl.ucsf.edu/Overview/software.html#dms
62. MS-DOCK: Accurate multiple conformation generator and rigid docking protocol for multi-step virtual ligand screening. N Sauton D Lagorce BO Villoutreix MA Miteva, BMC Bioinformatics 2008 9 184 10.1186/1471-2105-9-184 18402678
63. Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. RL DesJarlais RP Sheridan GL Seibel JS Dixon ID Kuntz R Venkataraghavan, J Med Chem 1988 31 722 729 10.1021/jm00399a006 3127588 (Pubitemid 18097087)
64. DG-AMMOS: A New tool to generate 3D conformation of small molecules using Distance Geometry and Automated Molecular Mechanics Optimization for in silico Screening. D Lagorce T Pencheva BO Villoutreix MA Miteva, BMC Chem Biol 2009 9 6 10.1186/1472-6769-9-6 19912625
65. Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate - DNA helices. J Srinivasan TE Cheatham P Cieplak PA Kollman DA Case, J am Chem Soc 1998 120 9401 9409 10.1021/ja981844+ (Pubitemid 28452628)
66. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. R Wang L Lai S Wang, J Comput Aided Mol Des 2002 16 11 26 10.1023/A:1016357811882 12197663 (Pubitemid 34855041)
67. The PyMOL Molecular Graphics System. WL Delano, DeLano Scientific 2002